Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01842139 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01842139 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 7 participants.
The verdict
NCT01842139, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This randomized phase I trial studies the side effects and best way to give vaccine therapy together with basiliximab in treating patients with acute myeloid leukemia (AML) in complete remission. Vaccines made from the WT1 peptide may help the body build an effective immune response to kill cancer cells. Montanide ISA 51 VG and poly-ICLC may enhance this response. Monoclonal antibodies, such as basiliximab, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. It is not yet known whether WT1 126-134 peptide vaccine with Montanide ISA 51 VG is more effective than with poly-ICLC when given together with basiliximab in treating AML
Interventions
- OTHER laboratory biomarker analysis
- DRUG Montanide ISA 51 VG
- BIOLOGICAL basiliximab
- BIOLOGICAL WT1 126-134 peptide vaccine
- DRUG poly ICLC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2011-12-05 |
| Est. Completion | 2018-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01842139
The ClinicalTrials.gov registry entry for NCT01842139 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01842139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01842139 about?
NCT01842139 is a clinical study titled "Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission". This randomized phase I trial studies the side effects and best way to give vaccine therapy together with basiliximab in treating patients with acute myeloid leukemia (AML) in complete remission. Vaccines made from the WT1 peptide may help the body build an effective immune response to kill cancer c...
What is the current status of trial NCT01842139?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2011-12-05. Estimated completion is 2018-03.
What interventions are being tested in trial NCT01842139?
The interventions under investigation include: laboratory biomarker analysis (OTHER), Montanide ISA 51 VG (DRUG), basiliximab (BIOLOGICAL), WT1 126-134 peptide vaccine (BIOLOGICAL), poly ICLC (DRUG).
Who is sponsoring clinical trial NCT01842139?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.